Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
about
Issues in solid-organ transplantation in children: translational research from bench to bedside.Posttransplant allosensitization in low immunological risk kidney and kidney-pancreas graft recipientsChallenges in pediatric renal transplantationUtility of HLA Antibody Testing in Kidney Transplantation.Application and interpretation of histocompatibility data in pediatric kidney transplantation.HLA-DQ Mismatches and Rejection in Kidney Transplant RecipientsImmunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity.Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney TransplantationRenal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes?Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation.Acute and chronic antibody-mediated rejection in pediatric kidney transplantation.Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.Clinical relevance of HLA antibody monitoring after kidney transplantation.Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection.De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients.Maintenance immunosuppressants in the management of antibody-mediated renal allograft rejection: which regimen is best?Relationship Among Viremia/Viral Infection, Alloimmunity, and Nutritional Parameters in the First Year After Pediatric Kidney Transplantation.Donor-specific HLA antibodies and graft function in kidney-transplanted children - the Vienna cohort.De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation.Minimum mycophenolic acid levels are associated with donor-specific antibody formation.De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability.Role of alloimmunity and autoimmunity in allograft rejection.Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: A 3-year prospective study.HLA-DQ Mismatching: Mounting Evidence for a Role in Kidney Transplant Rejection.Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies.Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.Development of immune response to tissue-restricted self-antigens in simultaneous kidney-pancreas transplant recipients with acute rejection.DQ molecules are the principal stimulators of de novo donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant.Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.Twenty-eight years of intestinal transplantation in Paris: experience of the oldest European center.De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis.Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients.Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.Preexisting anti-HLA donor-specific antibodies in pediatric renal transplant recipients - A new challenge?Post-transplantation-emerging anti-HLA DQA1/DQB1 antibody possibly responsible for graft rejection after myeloablative-unrelated marrow grafting.Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.Influence of de novo donor-specific antibody on early renal allograft function recovery.
P2860
Q27023312-0380EA65-09E0-4089-BB04-9D50AA195630Q33563056-F6B43DC4-1FC2-4B66-BA90-2C2DE7583BC7Q34761336-A26FEB28-4259-42F6-B7C6-99DD766510BDQ35790601-C3297685-2B12-4BF2-8824-6856D12C2747Q36380010-A4D13734-7508-4123-90EB-BB72E2370878Q36874597-F50776DB-1B28-4727-B0EA-2670F4C2B2C2Q37127201-F1FD1CE8-775F-4487-B9A0-EF073A8A0FB6Q37375622-5436CE12-B990-44E7-A8F5-9EDEAD0D19CCQ37481157-27C24702-73A0-466E-AC08-DDF92E938261Q37611251-33BF6E6C-8D23-49EC-9C7A-8C02C77B0A85Q37660263-8F2C2667-0018-466C-BBC2-C6DBAE9C4235Q38168293-5089234B-CFE3-476E-AB67-6B27D86A04F3Q38215262-224C0BD4-D12F-4ECA-A390-45D25FF13C62Q38262909-82A69882-2132-480C-B0E2-BB351ADB7102Q38265563-8946AAB3-43F4-44DD-8146-1E1336DF3050Q38282840-9EF00659-81B2-4486-A131-945A4C42C022Q38861456-9EA6ED0A-47C2-4005-A2C6-8838A0C65311Q39045577-F5C93713-B645-4C5B-B40E-4BAC95435D2AQ39091657-1FE86DA1-F603-49CD-B707-34140653B094Q39842547-32B0DFAF-9AFC-4E3B-8A6C-F21CBA41E533Q39928595-C77E38C4-8150-4A23-A99D-8294875C901AQ40295063-9E234FB7-F11D-41D7-B643-D4DA92BD9EADQ40468571-BC98E3FD-5930-45CF-8F07-2D26421D01FDQ41226453-EF0BC80B-8D17-4A40-942A-B004A7ECFD7CQ42253765-4D184134-4005-45D5-9E76-7096D342C91AQ42824238-BB608A25-0BAC-49C5-BDD6-21F68B846CC2Q44458696-D224C03F-134C-45FA-8B50-FC55D483537CQ44522008-9FE56496-976C-4F9F-AE6A-9B2931017E39Q45982490-280DF47B-F5D6-41EC-94B2-DBDDEA673518Q46938131-F2882B64-0E96-4BAF-822C-C6D364C8C661Q47574733-7C1950F6-C4C5-4471-83FC-D89FD00CF628Q48196510-1E8559D7-B612-454F-AF70-431533CB3F32Q48955987-FBDFB693-7406-4A95-8590-B0DFC55140EAQ50266397-AA3B2CE9-95DC-4DA4-892C-5F0A2E059473Q51563025-0B5FE0BC-D8C7-47CD-B1D6-19DC4203801CQ51585363-9F3680DD-6EE7-4280-BF1D-FE6A2D6A9CD1Q52842569-FD243580-B571-4C11-88BF-B329752EB995Q52897637-C7843995-F56F-44A9-8C72-8265E46F9C78Q53551249-DF91061B-3B84-449D-B40A-2B5DBA240F16Q53603593-514E1E8C-7484-46AA-BAE3-B3782FDDB32A
P2860
Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@en
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@nl
type
label
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@en
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@nl
prefLabel
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@en
Posttransplant de novo donor-s ...... e antibody-mediated rejection.
@nl
P2093
P2860
P50
P1476
Posttransplant de novo donor-s ...... te antibody-mediated rejection
@en
P2093
A Innocente
A Magnasco
A Tagliamacco
P2860
P304
P356
10.1111/J.1600-6143.2012.04251.X
P407
P577
2012-09-07T00:00:00Z